FBIOP Key Statistics, Chart & Performance
The current stock price of FBIOP is 7.72 USD. In the past month the price increased by 13.65%. In the past year, price increased by 10.32%.
FBIOP Latest News, Press Relases and Analysis
FBIOP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B |
Related stock screener links
About FBIOP
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA US
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ
Can you describe the business of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
What is the stock price of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP today?
The current stock price of FBIOP is 7.72 USD. The price increased by 3.62% in the last trading session.
Does FBIOP stock pay dividends?
FBIOP does not pay a dividend.
What is the ChartMill rating of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP stock?
FBIOP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does FORTRESS BIOTECH INC - FBIO 9 3/8 PERP belong to?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP)?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
When is the next dividend date for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP)?
The next ex-dividend date for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is June 14, 2024.
FBIOP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to FBIOP. When comparing the yearly performance of all stocks, FBIOP is a bad performer in the overall market: 62.43% of all stocks are doing better.
FBIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBIOP. FBIOP has a bad profitability rating. Also its financial health evaluation is rather negative.
FBIOP Financial Highlights
Over the last trailing twelve months FBIOP reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 57.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.94% | ||
| ROE | -9.55% | ||
| Debt/Equity | 0.86 |
FBIOP Forecast & Estimates
8 analysts have analysed FBIOP and the average price target is 28.51 USD. This implies a price increase of 269.29% is expected in the next year compared to the current price of 7.72.
For the next year, analysts expect an EPS growth of 80.35% and a revenue growth 24.62% for FBIOP